Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations.
All content for Beyond the Endpoint is the property of Duke Clinical Research Institute and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations.
Beyond the Headlines: Protein myths. Anti-aging hype. Autism research. A new diabetes drug?
Beyond the Endpoint
24 minutes 53 seconds
6 months ago
Beyond the Headlines: Protein myths. Anti-aging hype. Autism research. A new diabetes drug?
In this new episode of the Beyond the Endpoint series, “Beyond the Headlines,” hosts Emily O’Brien and Manesh Patel break down what’s you should know about these trending medical topics.
From hype to headlines—get clinical insight that goes deeper.
Access resources related to this episode https://dcri.org/blog/ep-9-beyond-headlines
187880
Beyond the Endpoint
Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations.
